Cargando…

Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study

AIMS: To describe the characteristics of patients receiving evolocumab in clinical practice across 12 European countries and simulate the association between low-density lipoprotein cholesterol (LDL-C) reduction and cardiovascular (CV) risk reduction. METHODS AND RESULTS: The characteristics of hype...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ray, Kausik K, Dhalwani, Nafeesa, Sibartie, Mahendra, Bridges, Ian, Ebenbichler, Christoph, Perrone-Filardi, Pasquale, Villa, Guillermo, Vogt, Anja, Bruckert, Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170569/ https://www.ncbi.nlm.nih.gov/pubmed/35175350 http://dx.doi.org/10.1093/ehjqcco/qcac009

Ejemplares similares

Evolocumab is initiated in Central and Eastern Europe at Much Higher LDL-C Levels than Recommended in Guidelines: Results from the Observational HEYMANS Study
por: Blaha, V, et al.
Publicado: (2023)

Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges
por: Packard, Chris, et al.
Publicado: (2021)

Intracavitary brachytherapy with additional Heyman capsules in the treatment of cervical cancer
por: Scharl, Sophia, et al.
Publicado: (2022)

Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
por: Mohamed, Farzahna, et al.
Publicado: (2023)

Towards the Sensory Nature of the Carotid Body: Hering, De Castro and Heymans†
por: de Castro, Fernando
Publicado: (2009)

Modified Heyman packing performed with small number of Simon-Norman catheters
por: Pálvölgyi, Jenö, et al.
Publicado: (2010)

Low‐Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events
por: Willeit, Peter, et al.
Publicado: (2020)

Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration
por: Ference, Brian A, et al.
Publicado: (2018)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
por: Shapiro, Michael D., et al.
Publicado: (2019)

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
por: Schwartz, Gregory G., et al.
Publicado: (2021)

Proportion of High-Risk/Very High-Risk Patients in Europe with Low-Density Lipoprotein Cholesterol at Target According to European Guidelines: A Systematic Review
por: Bruckert, Eric, et al.
Publicado: (2020)

Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD
por: Massy, Ziad A., et al.
Publicado: (2019)

Resistin Modulates Low-Density Lipoprotein Cholesterol Uptake in Human Placental Explants via PCSK9
por: Nava-Salazar, Sonia, et al.
Publicado: (2022)

PCSK9 and triglyceride-rich lipoprotein metabolism
por: Druce, Irena, et al.
Publicado: (2015)

Feasibility and preliminary efficacy of the ‘HEYMAN’ healthy lifestyle program for young men: a pilot randomised controlled trial
por: Ashton, Lee M., et al.
Publicado: (2017)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol
por: Poirier, Steve, et al.
Publicado: (2013)

Study on Regulation of Low Density Lipoprotein Cholesterol Metabolism using PCSK9 Gene Silencing: A computational Approach
por: Vijayaraghavan, Bhooma, et al.
Publicado: (2018)

Rare and common variants of APOB and PCSK9 in Korean patients with extremely low low-density lipoprotein-cholesterol levels
por: Lee, Chan Joo, et al.
Publicado: (2017)

PCSK9 Inhibition: Does Lipoprotein Size Matter?
por: Si‐Tayeb, Karim, et al.
Publicado: (2015)

Lipoprotein(a) and PCSK9 inhibition: clinical evidence
por: Ruscica, Massimiliano, et al.
Publicado: (2020)

Candidate Gene Analysis Reveals Strong Association of CETP Variants With High Density Lipoprotein Cholesterol and PCSK9 Variants With Low Density Lipoprotein Cholesterol in Ghanaian Adults: An AWI-Gen Sub-Study
por: Agongo, Godfred, et al.
Publicado: (2020)

Coronary Endothelial Dysfunction Is Associated With Elevated Serum PCSK9 Levels in People With HIV Independent of Low‐Density Lipoprotein Cholesterol
por: Leucker, Thorsten M., et al.
Publicado: (2018)

PCSK9: The Nexus of Lipoprotein Metabolism and Inflammation in COVID-19
por: Goonewardena, Sascha N., et al.
Publicado: (2023)

Factors Associated With Enhanced Low‐Density Lipoprotein Cholesterol Lowering With Bempedoic Acid
por: Ballantyne, Christie M., et al.
Publicado: (2022)

HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”
por: Kohli, Payal, et al.
Publicado: (2016)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
por: Afanasieva, Olga, et al.
Publicado: (2020)

Threshold Effects in the Relationship Between Serum Non-High-Density Lipoprotein Cholesterol and Metabolic Syndrome
por: Wang, Saibin, et al.
Publicado: (2019)

Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
por: Sinning, David, et al.
Publicado: (2020)

A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9
por: Zeitlinger, Markus, et al.
Publicado: (2021)

Common and Rare PCSK9 Variants Associated with Low-Density Lipoprotein Cholesterol Levels and the Risk of Diabetes Mellitus: A Mendelian Randomization Study
por: Hsu, Lung-An, et al.
Publicado: (2022)

The Emergence of HIV Transmitted Resistance in Botswana: “When Will the WHO Detection Threshold Be Exceeded?”
por: Vardavas, Raffaele, et al.
Publicado: (2007)

Trends and threshold exceedances analysis of airborne pollen concentrations in Metropolitan Santiago Chile
por: Toro A., Richard, et al.
Publicado: (2015)

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans
por: Reyes-Soffer, Gissette, et al.
Publicado: (2017)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

Assessing the Accuracy of Estimated Lipoprotein(a) Cholesterol and Lipoprotein(a)‐Free Low‐Density Lipoprotein Cholesterol
por: Zheng, Weili, et al.
Publicado: (2022)

Low-density lipoprotein cholesterol goal attainment in Germany: Results from the DA VINCI study
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2022)

Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation
por: Kosenko, Tanja, et al.
Publicado: (2013)

Furin-cleaved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Active and Modulates Low Density Lipoprotein Receptor and Serum Cholesterol Levels
por: Lipari, Michael T., et al.
Publicado: (2012)

dB/dt Evaluation in MRI Sites: Is ICNIRP Threshold Limit (for Workers) Exceeded?
por: Acri, Giuseppe, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tlf925k81v590v2t0ng8t5oqub